These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15085469)

  • 1. Heparin to pentasaccharide and beyond: the end is not in sight.
    Messmore HL; Wehrmacher WH; Coyne E; Fareed J
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():81-8. PubMed ID: 15085469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heparin therapy: 1998 (current use of the 80-year-old heparin)].
    Rák K
    Orv Hetil; 1999 Jan; 140(2):59-66. PubMed ID: 9949661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose heparin to low molecular weight heparin prophylaxis: in pursuit of excellence - a personal perspective.
    Kakkar VV
    J Thromb Haemost; 2005 Feb; 3(2):195-209. PubMed ID: 15670017
    [No Abstract]   [Full Text] [Related]  

  • 5. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A century of heparin: past, present and future.
    Hemker HC
    J Thromb Haemost; 2016 Dec; 14(12):2329-2338. PubMed ID: 27862941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History of heparin.
    Barrowcliffe TW
    Handb Exp Pharmacol; 2012; (207):3-22. PubMed ID: 22566218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin: from animal organ extract to designer drug.
    Middeldorp S
    Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The unknown history of heparin's discovery].
    Dinis da Gama A
    Rev Port Cir Cardiotorac Vasc; 2008; 15(1):25-30. PubMed ID: 18618048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin, the miracle drug: a brief history of its discovery.
    Ancalmo N; Ochsner J
    J La State Med Soc; 1990 Sep; 142(9):22-4. PubMed ID: 2230527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The prophylaxis against venous thromboembolic complications in internal medicine--the gap between theory and practice].
    Hirmerová J
    Vnitr Lek; 2006 Apr; 52(4):379-88. PubMed ID: 16755994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- and ultra-low-molecular-weight heparins.
    Kakkar AK
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):77-87. PubMed ID: 15171959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombosis prophylaxis with heparins in intensive care patients].
    Greinacher A; Janssen D
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2005 Mar; 40(3):156-63. PubMed ID: 15770559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparins, low-molecular-weight heparins, and pentasaccharides.
    Dinwoodey DL; Ansell JE
    Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.